writes copy 13 Dec 2017

3D Printing News Briefs: December 12 2017

Sponsored Content

Today’s 3D Printing News Briefs features some of the latest happenings in medical, business, and education 3D printing news. Nanoscribe is celebrating its 10 year anniversary, while an industry expert weighs in on the latest FDA 3D printing guidance, EIT and HCA have signed an agreement for 3D printed interbody products, and Aprecia is teaming up with another pharmaceutical company to develop 3D printed orphan drugs. After putting the Stratasys Fortus 450mc 3D printer to work, a Spanish aerospace and engineering company is welcoming some new business, and Polish 3D printer manufacturer Graften is expanding its 3D printers to the UK market. Education is in focus as a community college in Kentucky is offering an additive manufacturing certification course. Finally,  Tinkercad and MyMiniFactory are running a Christmas 3D design challenge, to round out our roundup on a fun note.

Nanoscribe Celebrating Tenth Anniversary

10 Years of Nanoscribe (L-R): The co-founders of Nanoscribe, Dr. Michael Thiel (CSO) and Martin Hermatschweiler (CEO) manage the operational business of Nanoscribe.

German 3D printer manufacturer Nanoscribe GmbH, a spin-off of  Karlsruhe Institute of Technology (KIT), is celebrating a very important anniversary – it was founded on this day 10 years ago. Nanoscribe has grown exponentially over the last decade, now serving over 1,000 users and enjoying double-digit million revenues for the last three years, and is now a 3D printing leader  in both the nano- and micrometer scales. The award-winning company, which places a high priority on connecting science and industry, has expanded its number of employees by 25% CAGR over the last five years, and has set new standards in the microfabrication field, so its users can fabricate macroscopic 3D objects at the micrometer scale.

“We took the unknown technology of two-photon-polymerization out of a research niche,” said Nanoscribe Co-Founder Prof. Dr. Martin Wegener,  professor at the Institute of Applied Physics and director of the Institute for Nanotechnology at KIT. “Because of the great interest, as well as the high technical complexity, the idea emerged to make this capacity available as a commercial product to laboratories around the world.”

The company is looking ahead to the future, with plans to move into a new building at the KIT Campus North within the next two years.

3D Printing Industry Expert Laura Gilmour Makes Statement on New FDA Guidance

Laura Gilmour [Image: EOS]

Last week, the US Food and Drug Administration (FDA) issued new guidance on the technical aspects of 3D printing for medical device manufacturers, and people in the 3D printing industry are starting to comment. Industry expert Laura Gilmour, who once worked at the FDA reviewing and clearing orthopedic devices, is the Medical Account Manager of EOS North America, and oversees over 20 medical device OEMs and contract manufacturers that use EOS technology. She spent 15 years as a biomedical research and development engineer and worked with EOS in a customer capacity until joining the company last year. Gilmour, who will be speaking at our upcoming AM Strategies summit, is more than qualified to offer industry commentary on the FDA’s new 3D printing guidance.

“The FDA finalizing their technical guidance document on additive manufacturing means a lot for the industry, since the medical sector was an early adopter of additive manufacturing for device production,” Gilmour said. “As the wording in this document confirms, the FDA recognizes the importance of the interaction between material, machine, and process for a quality part; this is already a central pillar of the way EOS develops processes and supports our customers. EOS's rigorously tested systems give manufacturers in the medical field the ability to change variables in the process while maintaining the guidance given by the FDA. It is refreshing to see the U.S. regulatory body acknowledge the importance of material, machine and process interaction to provide high quality medical devices to patients.”

EIT and HCA Announce Agreement

Medical device manufacturer Emerging Implant Technologies (EIT), headquartered in Germany and focused on 3D printed spinal solutions, has completed the contracting process with HealthTrust related to its  new agreement with HCA, the largest GPO in the US. The company can now offer all of its 3D printed interbody products, which are made with its 3D printed porous Cellular Titanium structures, for ALIF, Cervical, PLIF, and TLIF procedures in HCA’s 177 hospitals and 119 surgery centers. The approval of the contract, which will help EIT continue its “aggressive growth pattern” in the country, was pursued and completed by Ortho Sales Partners (OSP). EIT is also working to finalize an action plan with HCA’s leadership to fully understand the economic impact its technology will have on implant costs, fusion rates, and osteobiologics.

“EIT ´s goal is to improve spine care using the advantages of 3D printing technology and cope with given pricing and reimbursement structures,” explained EIT’s CEO and Co-Founder  Guntmar Eisen. “We are delighted that HCA/HealthTrust is interested in working with EIT. This will help us to get quicker market access in the United States.”

Aprecia  Pharmaceuticals Enters Partnership to Develop 3D Printed Orphan Drugs

Read the Original Article